

Lorenzo Leggio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1093539/publications.pdf>

Version: 2024-02-01

218
papers

9,774
citations

29994

54
h-index

51492

86
g-index

224
all docs

224
docs citations

224
times ranked

8083
citing authors

#	ARTICLE	IF	CITATIONS
1	Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. <i>Lancet</i> , The, 2007, 370, 1915-1922.	6.3	611
2	Acute alcohol intoxication. <i>European Journal of Internal Medicine</i> , 2008, 19, 561-567.	1.0	270
3	Advances in the science and treatment of alcohol use disorder. <i>Science Advances</i> , 2019, 5, eaax4043.	4.7	265
4	Transcranial magnetic stimulation of dorsolateral prefrontal cortex reduces cocaine use: A pilot study. <i>European Neuropsychopharmacology</i> , 2016, 26, 37-44.	0.3	245
5	Oxytocin by intranasal and intravenous routes reaches the cerebrospinal fluid in rhesus macaques: determination using a novel oxytocin assay. <i>Molecular Psychiatry</i> , 2018, 23, 115-122.	4.1	201
6	Rehabilitating the addicted brain with transcranial magnetic stimulation. <i>Nature Reviews Neuroscience</i> , 2017, 18, 685-693.	4.9	184
7	Baclofen in the Treatment of Alcohol Withdrawal Syndrome: A Comparative Study vs Diazepam. <i>American Journal of Medicine</i> , 2006, 119, 276.e13-276.e18.	0.6	173
8	Typologies of Alcohol Dependence. From Jellinek to Genetics and Beyond. <i>Neuropsychology Review</i> , 2009, 19, 115-129.	2.5	173
9	Dose-Response Effect of Baclofen in Reducing Daily Alcohol Intake in Alcohol Dependence: Secondary Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Alcohol and Alcoholism</i> , 2011, 46, 312-317.	0.9	173
10	Liver Transplantation in Alcoholic Patients: Impact of an Alcohol Addiction Unit Within a Liver Transplant Center. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, 1601-1608.	1.4	156
11	Relationship Between Ghrelin Levels, Alcohol Craving, and Nutritional Status in Current Alcoholic Patients. <i>Alcoholism: Clinical and Experimental Research</i> , 2006, 30, 1933-1937.	1.4	154
12	Neurobiochemical and clinical aspects of craving in alcohol addiction: A review. <i>Addictive Behaviors</i> , 2005, 30, 1209-1224.	1.7	147
13	Alcohol use disorders in the elderly: A brief overview from epidemiology to treatment options. <i>Experimental Gerontology</i> , 2012, 47, 411-416.	1.2	132
14	The CRF1 Antagonist Verucerfont in Anxious Alcohol-Dependent Women: Translation of Neuroendocrine, But not of Anti-Craving Effects. <i>Neuropsychopharmacology</i> , 2016, 41, 2818-2829.	2.8	128
15	Identification and Management of Alcohol Withdrawal Syndrome. <i>Drugs</i> , 2015, 75, 353-365.	4.9	127
16	Intravenous Ghrelin Administration Increases Alcohol Craving in Alcohol-Dependent Heavy Drinkers: A Preliminary Investigation. <i>Biological Psychiatry</i> , 2014, 76, 734-741.	0.7	126
17	State and trait anxiety and depression in patients affected by gastrointestinal diseases: psychometric evaluation of 1641 patients referred to an internal medicine outpatient setting. <i>International Journal of Clinical Practice</i> , 2008, 62, 1063-1069.	0.8	120
18	Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving. <i>Addiction Biology</i> , 2012, 17, 452-464.	1.4	118

#	ARTICLE	IF	CITATIONS
19	How Many Cravings? Pharmacological Aspects of Craving Treatment in Alcohol Addiction: A Review. <i>Neuropsychobiology</i> , 2005, 51, 59-66.	0.9	117
20	State and trait anxiety and depression in patients with primary brain tumors before and after surgery: 1-year longitudinal study. <i>Journal of Neurosurgery</i> , 2008, 108, 281-286.	0.9	108
21	Treatment of Alcohol Use Disorder in Patients with Alcoholic Liver Disease. <i>American Journal of Medicine</i> , 2017, 130, 124-134.	0.6	107
22	Effectiveness and Safety of Baclofen in the Treatment of Alcohol Dependent Patients. <i>CNS and Neurological Disorders - Drug Targets</i> , 2010, 9, 33-44.	0.8	104
23	Addiction as a brain disease revised: why it still matters, and the need for consilience. <i>Neuropsychopharmacology</i> , 2021, 46, 1715-1723.	2.8	103
24	Association of the 5-HTT gene-linked promoter region (5-HTTLPR) polymorphism with psychiatric disorders: review of psychopathology and pharmacotherapy. <i>Pharmacogenomics and Personalized Medicine</i> , 2012, 5, 19.	0.4	95
25	New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focus on non-benzodiazepine GABAergic medications. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1106-1117.	2.5	94
26	Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. <i>Lancet Psychiatry</i> , 2018, 5, 957-960.	3.7	94
27	Bots and Misinformation Spread on Social Media: Implications for COVID-19. <i>Journal of Medical Internet Research</i> , 2021, 23, e26933.	2.1	94
28	Interventions and Manipulations of Interoception. <i>Trends in Neurosciences</i> , 2021, 44, 52-62.	4.2	92
29	Psychological support counselling improves gluten-free diet compliance in coeliac patients with affective disorders. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 777-782.	1.9	90
30	The novel ghrelin receptor inverse agonist PF-5190457 administered with alcohol: preclinical safety experiments and a phase 1b human laboratory study. <i>Molecular Psychiatry</i> , 2020, 25, 461-475.	4.1	90
31	Management of Alcohol Dependence in Patients with Liver Disease. <i>CNS Drugs</i> , 2013, 27, 287-299.	2.7	87
32	Safety and Efficacy of Baclofen in the Treatment of Alcohol-Dependent Patients. <i>Current Pharmaceutical Design</i> , 2010, 16, 2113-2117.	0.9	86
33	Targeting the Oxytocin System to Treat Addictive Disorders: Rationale and Progress to Date. <i>CNS Drugs</i> , 2016, 30, 109-123.	2.7	86
34	Baclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety. <i>Alcohol and Alcoholism</i> , 2014, 49, 654-660.	0.9	82
35	Exogenous ghrelin administration increases alcohol self-administration and modulates brain functional activity in heavy-drinking alcohol-dependent individuals. <i>Molecular Psychiatry</i> , 2018, 23, 2029-2038.	4.1	82
36	Ghrelin: From a gut hormone to a potential therapeutic target for alcohol use disorder. <i>Physiology and Behavior</i> , 2019, 204, 49-57.	1.0	80

#	ARTICLE	IF	CITATIONS
37	The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence. <i>Translational Psychiatry</i> , 2015, 5, e583-e583.	2.4	79
38	Cutaneous manifestations in celiac disease. <i>World Journal of Gastroenterology</i> , 2006, 12, 843.	1.4	77
39	Current and Promising Pharmacotherapies, and Novel Research Target Areas in the Treatment of Alcohol Dependence: A Review. <i>Current Pharmaceutical Design</i> , 2011, 17, 1323-1332.	0.9	74
40	Novel Therapeutic Strategies for Alcohol and Drug Addiction: Focus on GABA, Ion Channels and Transcranial Magnetic Stimulation. <i>Neuropsychopharmacology</i> , 2012, 37, 163-177.	2.8	74
41	The Role of the Ghrelin System in Drug Addiction. <i>International Review of Neurobiology</i> , 2017, 136, 89-119.	0.9	74
42	Oxytocin blocks enhanced motivation for alcohol in alcohol dependence and blocks alcohol effects on GABAergic transmission in the central amygdala. <i>PLoS Biology</i> , 2019, 17, e2006421.	2.6	73
43	Sex Differences in Opioid and Psychostimulant Craving and Relapse: A Critical Review. <i>Pharmacological Reviews</i> , 2022, 74, 119-140.	7.1	72
44	Review of Topiramate: An Antiepileptic for the Treatment of Alcohol Dependence. <i>Current Drug Abuse Reviews</i> , 2009, 2, 135-142.	3.4	66
45	Role of Feeding-Related Pathways in Alcohol Dependence: A Focus on Sweet Preference, NPY, and Ghrelin. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, 194-202.	1.4	66
46	A human laboratory pilot study with baclofen in alcoholic individuals. <i>Pharmacology Biochemistry and Behavior</i> , 2013, 103, 784-791.	1.3	66
47	The Microbiota, the Gut and the Brain in Eating and Alcohol Use Disorders: A "MÃ©nage Ã Trois"?. <i>Alcohol and Alcoholism</i> , 2017, 52, 403-413.	0.9	66
48	Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection. <i>Addictive Behaviors</i> , 2012, 37, 561-564.	1.7	65
49	Pharmacological Approaches to Reducing Craving in Patients with Alcohol Use Disorders. <i>CNS Drugs</i> , 2014, 28, 343-360.	2.7	65
50	Baclofen: a new drug for the treatment of alcohol dependence. <i>International Journal of Clinical Practice</i> , 2006, 60, 1003-1008.	0.8	63
51	The therapeutic potential of gamma-hydroxybutyric acid for alcohol dependence: balancing the risks and benefits. A focus on clinical data. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 675-686.	1.9	63
52	The gut in the brain: the effects of bariatric surgery on alcohol consumption. <i>Addiction Biology</i> , 2017, 22, 1540-1553.	1.4	61
53	Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 158-169.	1.4	60
54	Role of the α_1 blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial. <i>Addiction Biology</i> , 2016, 21, 904-914.	1.4	58

#	ARTICLE	IF	CITATIONS
55	Rapid Regression of Psoriasis in a Coeliac Patient after Gluten-Free Diet. <i>Digestion</i> , 2003, 68, 9-12.	1.2	57
56	Suppression of Alcohol Delirium Tremens by Baclofen Administration: A Case Report. <i>Clinical Neuropharmacology</i> , 2003, 26, 258-262.	0.2	56
57	Differences Between Treatment-Seeking and Nontreatment-Seeking Alcohol-Dependent Research Participants: An Exploratory Analysis. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 414-420.	1.4	55
58	Noradrenergic targets for the treatment of alcohol use disorder. <i>Psychopharmacology</i> , 2018, 235, 1625-1634.	1.5	51
59	Sex differences in the response to opioids for pain relief: A systematic review and meta-analysis. <i>Pharmacological Research</i> , 2019, 148, 104447.	3.1	50
60	Management of alcohol use disorder in patients with cirrhosis in the setting of liver transplantation. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 45-59.	8.2	50
61	Primary renal angiosarcoma: A rare malignancy. A case report and review of the literature†. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006, 24, 307-312.	0.8	48
62	Effects of oral, smoked, and vaporized cannabis on endocrine pathways related to appetite and metabolism: a randomized, double-blind, placebo-controlled, human laboratory study. <i>Translational Psychiatry</i> , 2020, 10, 71.	2.4	48
63	Social phobia in coeliac disease. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 410-415.	0.6	47
64	Increased Serum High-density Lipoprotein-Cholesterol Concentration in Celiac Disease After Gluten-free Diet Treatment Correlates With Body Fat Stores. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 946-949.	1.1	47
65	Stress, Motivation, and the Gut-Brain Axis: A Focus on the Ghrelin System and Alcohol Use Disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 1378-1389.	1.4	47
66	The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective. <i>Frontiers in Psychiatry</i> , 2018, 9, 708.	1.3	47
67	Reduced plasma ghrelin concentrations are associated with decreased brain reactivity to food cues after laparoscopic sleeve gastrectomy. <i>Psychoneuroendocrinology</i> , 2019, 100, 229-236.	1.3	47
68	Role of the GABAB receptor system in alcoholism and stress: focus on clinical studies and treatment perspectives. <i>Alcohol</i> , 2009, 43, 559-563.	0.8	46
69	A Within-Group Design of Nontreatment Seeking 5-HTTLPR Genotyped Alcohol-Dependent Subjects Receiving Ondansetron and Sertraline. <i>Alcoholism: Clinical and Experimental Research</i> , 2009, 33, 315-323.	1.4	45
70	Biobehavioral effects of baclofen in anxious alcohol-dependent individuals: a randomized, double-blind, placebo-controlled, laboratory study. <i>Translational Psychiatry</i> , 2017, 7, e1108-e1108.	2.4	45
71	Role of the ghrelin system in alcoholism: Acting on the growth hormone secretagogue receptor to treat alcohol-related diseases. <i>Drug News and Perspectives</i> , 2010, 23, 157.	1.9	45
72	Roux-en-Y Gastric Bypass Increases Intravenous Ethanol Self-Administration in Dietary Obese Rats. <i>PLoS ONE</i> , 2013, 8, e83741.	1.1	44

#	ARTICLE	IF	CITATIONS
73	Repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex may improve symptoms of anhedonia in individuals with cocaine use disorder: A pilot study. <i>Brain Stimulation</i> , 2018, 11, 1195-1197.	0.7	44
74	Insulin But Not Insulin Growth Factorâ€1 Correlates With Craving in Currently Drinking Alcoholâ€Dependent Patients. <i>Alcoholism: Clinical and Experimental Research</i> , 2008, 32, 450-458.	1.4	43
75	Pharmacotherapy for alcoholic patients with alcoholic liver disease. <i>American Journal of Health-System Pharmacy</i> , 2014, 71, 1265-1276.	0.5	42
76	A relationship between the aldosteroneâ€mineralocorticoid receptor pathway and alcohol drinking: preliminary translational findings across rats, monkeys and humans. <i>Molecular Psychiatry</i> , 2018, 23, 1466-1473.	4.1	41
77	Fasting-induced increase in plasma ghrelin is blunted by intravenous alcohol administration: A within-subject placebo-controlled study. <i>Psychoneuroendocrinology</i> , 2013, 38, 3085-3091.	1.3	40
78	New Challenges in Addiction Medicine: COVID-19 Infection in Patients With Alcohol and Substance Use Disordersâ€The Perfect Storm. <i>American Journal of Psychiatry</i> , 2020, 177, 805-807.	4.0	40
79	Relationship Between the Hypothalamicâ€Pituitaryâ€Thyroid Axis and Alcohol Craving in Alcoholâ€Dependent Patients: A Longitudinal Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2008, 32, 2047-2053.	1.4	38
80	Incidence of craving for and abuse of gamma-hydroxybutyric acid (GHB) in different populations of treated alcoholics: an open comparative study. <i>Journal of Psychopharmacology</i> , 2009, 23, 883-890.	2.0	38
81	Higher pretreatment blood pressure is associated with greater alcohol drinking reduction in alcohol-dependent individuals treated with doxazosin. <i>Drug and Alcohol Dependence</i> , 2017, 177, 23-28.	1.6	38
82	Affective and Psychiatric Disorders in Celiac Disease. <i>Digestive Diseases</i> , 2008, 26, 140-148.	0.8	37
83	Renin and aldosterone but not the natriuretic peptide correlate with obsessive craving in medium-term abstinent alcohol-dependent patients: a longitudinal study. <i>Alcohol</i> , 2008, 42, 375-381.	0.8	36
84	Small-Fiber Degeneration in Alcohol-Related Peripheral Neuropathy. <i>Alcoholism: Clinical and Experimental Research</i> , 2014, 38, 1965-1972.	1.4	36
85	Leptin levels are reduced by intravenous ghrelin administration and correlated with cue-induced alcohol craving. <i>Translational Psychiatry</i> , 2015, 5, e646-e646.	2.4	36
86	A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. <i>Psychopharmacology</i> , 2015, 232, 233-243.	1.5	36
87	Ghrelin receptor deletion reduces bingeâ€like alcohol drinking in rats. <i>Journal of Neuroendocrinology</i> , 2019, 31, e12663.	1.2	36
88	The treatment of alcohol and opioid dependence in pregnant women. <i>Current Opinion in Psychiatry</i> , 2012, 25, 559-564.	3.1	35
89	Acute effects of intravenous cocaine administration on serum concentrations of ghrelin, amylin, glucagon-like peptide-1, insulin, leptin and peptide YY and relationships with cardiorespiratory and subjective responses. <i>Drug and Alcohol Dependence</i> , 2017, 180, 68-75.	1.6	34
90	Effects of short-term moderate alcohol administration on oxidative stress and nutritional status in healthy males. <i>Appetite</i> , 2008, 50, 50-56.	1.8	33

#	ARTICLE	IF	CITATIONS
91	The Relationship of Appetitive, Reproductive and Posterior Pituitary Hormones to Alcoholism and Craving in Humans. <i>Neuropsychology Review</i> , 2012, 22, 211-228.	2.5	33
92	Metabolic and Nutritional Features in Adult Celiac Patients. <i>Digestive Diseases</i> , 2008, 26, 128-133.	0.8	32
93	Blood Glucose Level, Alcohol Heavy Drinking, and Alcohol Craving During Treatment for Alcohol Dependence: Results From the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2009, 33, 1539-1544.	1.4	31
94	Turning the Clock Ahead: Potential Preclinical and Clinical Neuropharmacological Targets for Alcohol Dependence. <i>Current Pharmaceutical Design</i> , 2010, 16, 2159-2181.	0.9	31
95	Role of Trait Anxiety in Persistent Radicular Pain After Surgery for Lumbar Disc Herniation. <i>Neurosurgery</i> , 2010, 67, 265-271.	0.6	31
96	Ondansetron Reduces Naturalistic Drinking in Nontreatment-Seeking Alcohol-Dependent Individuals with the LL 5-HTTLPR Genotype: A Laboratory Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2014, 38, 1567-1574.	1.4	31
97	Varenicline versus nicotine patch with brief advice for smokers with substance use disorders with or without depression: effects on smoking, substance use and depressive symptoms. <i>Addiction</i> , 2017, 112, 1808-1820.	1.7	31
98	Understanding and Treating Alcohol Craving and Dependence: Recent Pharmacological and Neuroendocrinological Findings. <i>Alcohol and Alcoholism</i> , 2009, 44, 341-352.	0.9	30
99	Preliminary findings on the use of metadoxine for the treatment of alcohol dependence and alcoholic liver disease. <i>Human Psychopharmacology</i> , 2011, 26, 554-559.	0.7	30
100	Roux-en-Y Gastric Bypass Alters Brain Activity in Regions that Underlie Reward and Taste Perception. <i>PLoS ONE</i> , 2015, 10, e0125570.	1.1	30
101	Oxytocin receptor mRNA expression in dorsolateral prefrontal cortex in major psychiatric disorders: A human post-mortem study. <i>Psychoneuroendocrinology</i> , 2018, 96, 143-147.	1.3	30
102	Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Suppress Voluntary Alcohol Intake in Male Wistar Rats. <i>Frontiers in Neuroscience</i> , 2020, 14, 599646.	1.4	30
103	A Phase I randomized clinical trial testing the safety, tolerability and preliminary pharmacokinetics of the mGluR5 negative allosteric modulator GET 73 following single and repeated doses in healthy volunteers. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 109, 78-85.	1.9	29
104	Using Machine Learning to Classify Individuals With Alcohol Use Disorder Based on Treatment Seeking Status. <i>EClinicalMedicine</i> , 2019, 12, 70-78.	3.2	29
105	Development and initial characterization of a novel ghrelin receptor CRISPR/Cas9 knockout wistar rat model. <i>International Journal of Obesity</i> , 2019, 43, 344-354.	1.6	29
106	Use of Novel Technology-Based Techniques to Improve Alcohol-Related Outcomes in Clinical Trials. <i>Alcohol and Alcoholism</i> , 2013, 48, 712-719.	0.9	28
107	Effect of alcohol use disorder on oxytocin peptide and receptor mRNA expression in human brain: A post-mortem case-control study. <i>Psychoneuroendocrinology</i> , 2017, 85, 14-19.	1.3	28
108	Coenzyme Q 10 and Cardiovascular Risk Factors in Idiopathic Sudden Sensorineural Hearing Loss Patients. <i>Otology and Neurotology</i> , 2007, 28, 878-883.	0.7	28

#	ARTICLE	IF	CITATIONS
109	Barriers to the management of alcohol use disorder and alcohol-associated liver disease: strategies to implement integrated care models. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 186-195.	3.7	28
110	The Leu72Met Polymorphism of the Prepro-ghrelin Gene is Associated With Alcohol Consumption and Subjective Responses to Alcohol: Preliminary Findings. <i>Alcohol and Alcoholism</i> , 2017, 52, 425-430.	0.9	26
111	Wilson's Disease: Clinical, Genetic and Pharmacological Findings. <i>International Journal of Immunopathology and Pharmacology</i> , 2005, 18, 7-14.	1.0	25
112	Hormones and drinking behaviour: New findings on ghrelin, insulin, leptin and volume-regulating hormones. An ESBRA Symposium report. <i>Drug and Alcohol Review</i> , 2009, 28, 160-165.	1.1	25
113	Understanding and Treating Patients With Alcoholic Cirrhosis: An Update. <i>Alcoholism: Clinical and Experimental Research</i> , 2009, 33, 1136-1144.	1.4	25
114	Prospects for pharmacotherapies to treat alcohol use disorder. <i>Current Opinion in Psychiatry</i> , 2019, 32, 255-265.	3.1	25
115	Comparing and Combining Topiramate and Aripiprazole on Alcohol-Related Outcomes in a Human Laboratory Study. <i>Alcohol and Alcoholism</i> , 2018, 53, 268-276.	0.9	24
116	Celiac disease and hearing loss: Preliminary data on a new possible association. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 1209-1213.	0.6	23
117	Baclofen in the treatment of persistent hiccup: a case series. <i>International Journal of Clinical Practice</i> , 2013, 67, 918-921.	0.8	22
118	Alcohol drinking patterns in young people: A survey-based study. <i>Journal of Health Psychology</i> , 2017, 22, 1889-1896.	1.3	22
119	Baclofen in the Treatment of Patients With Alcohol Use Disorder and Other Mental Health Disorders. <i>Frontiers in Psychiatry</i> , 2018, 9, 464.	1.3	22
120	The future of translational research on alcohol use disorder. <i>Addiction Biology</i> , 2021, 26, e12903.	1.4	22
121	Relationship between craving and plasma leptin concentrations in patients with cocaine addiction. <i>Psychoneuroendocrinology</i> , 2017, 85, 35-41.	1.3	21
122	A deeper insight into how GABA-B receptor agonism via baclofen may affect alcohol seeking and consumption: lessons learned from a human laboratory investigation. <i>Molecular Psychiatry</i> , 2021, 26, 545-555.	4.1	21
123	Is Cortisol Involved in the Alcohol-Related Fat Mass Impairment? A Longitudinal Clinical Study. <i>Alcohol and Alcoholism</i> , 2009, 44, 211-215.	0.9	20
124	Management of Alcohol Use Disorder in Patients Requiring Liver Transplant. <i>American Journal of Psychiatry</i> , 2015, 172, 1182-1189.	4.0	20
125	What the alcohol doctor ordered from the neuroscientist. <i>Progress in Brain Research</i> , 2016, 224, 401-418.	0.9	20
126	A Double-Blind Randomized Placebo-Controlled Trial of Oral Naltrexone for Heavy-Drinking Smokers Seeking Smoking Cessation Treatment. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 1201-1211.	1.4	20

#	ARTICLE	IF	CITATIONS
127	Impulsive Personality Traits Mediate the Relationship Between Adult Attentionâ€Deficit/Hyperactivity Symptoms and Alcohol Dependence Severity. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 173-183.	1.4	20
128	N-acetyl cysteine in the treatment of alcohol use disorder in patients with liver disease: Rationale for further research. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 667-675.	1.9	20
129	Ondansetron and sertraline may interact with 5-HTTLPR and DRD4 polymorphisms to reduce drinking in non-treatment seeking alcohol-dependent women: Exploratory findings. <i>Alcohol</i> , 2014, 48, 515-522.	0.8	19
130	Relationship Between the Thyroid Axis and Alcohol Craving. <i>Alcohol and Alcoholism</i> , 2015, 50, 24-29.	0.9	19
131	Advances in Pharmacotherapy Development: Human Clinical Studies. <i>Handbook of Experimental Pharmacology</i> , 2017, 248, 579-613.	0.9	19
132	Pharmacological manipulation of the ghrelin system and alcohol hangover symptoms in heavy drinking individuals: Is there a link?. <i>Pharmacology Biochemistry and Behavior</i> , 2018, 172, 39-49.	1.3	19
133	Medication Development for Alcohol Use Disorder: A Focus on Clinical Studies. <i>Handbook of Experimental Pharmacology</i> , 2019, 258, 443-462.	0.9	19
134	Endocrine effects of the novel ghrelin receptor inverse agonist PF-5190457: Results from a placebo-controlled human laboratory alcohol co-administration study in heavy drinkers. <i>Neuropharmacology</i> , 2020, 170, 107788.	2.0	19
135	From â€œHunger Hormoneâ€ to â€œItâ€™s Complicatedâ€: Ghrelin Beyond Feeding Control. <i>Physiology</i> , 2022, 37, 5-15.	1.6	19
136	Ghrelin Receptor Influence on Cocaine Reward is Not Directly Dependent on Peripheral Acyl-Ghrelin. <i>Scientific Reports</i> , 2019, 9, 1841.	1.6	18
137	New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1291-1303.	0.9	18
138	The Amygdala Noradrenergic System Is Compromised With Alcohol Use Disorder. <i>Biological Psychiatry</i> , 2022, 91, 1008-1018.	0.7	18
139	Invited Commentary * Serotonin transporter (SERT) brain density and neurobiological cloning subtypes model: a lesson by human autoradiography studies. <i>Alcohol and Alcoholism</i> , 2008, 43, 148-150.	0.9	17
140	Five Priority Areas for Improving Medications Development for Alcohol Use Disorder and Promoting Their Routine Use in Clinical Practice. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 23-35.	1.4	17
141	Differential correlation of serum BDNF and microRNA content in rats with rapid or late onset of heavy alcohol use. <i>Addiction Biology</i> , 2021, 26, e12890.	1.4	17
142	A closer look at alcoholâ€induced changes in the ghrelin system: novel insights from preclinical and clinical data. <i>Addiction Biology</i> , 2022, 27, e13033.	1.4	17
143	The influence of anxiety symptoms on clinical outcomes during baclofen treatment of alcohol use disorder: A systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 125, 296-313.	2.9	17
144	A safety and tolerability laboratory study of the combination of aripiprazole and topiramate in volunteers who drink alcohol. <i>Human Psychopharmacology</i> , 2009, 24, 465-472.	0.7	15

#	ARTICLE	IF	CITATIONS
145	Combined Pharmacotherapies for the Management of Alcoholism: Rationale and Evidence to Date. <i>CNS Drugs</i> , 2014, 28, 107-119.	2.7	15
146	Parsing out the role of dopamine D4 receptor gene (DRD4) on alcohol-related phenotypes: A meta-analysis and systematic review. <i>Addiction Biology</i> , 2020, 25, e12770.	1.4	15
147	Dataset for Phase I randomized clinical trial for safety and tolerability of GET 73 in single and repeated ascending doses including preliminary pharmacokinetic parameters. <i>Data in Brief</i> , 2017, 15, 407-413.	0.5	13
148	Effects of exogenous ghrelin administration and ghrelin receptor blockade, in combination with alcohol, on peripheral inflammatory markers in heavy-drinking individuals: Results from two human laboratory studies. <i>Brain Research</i> , 2020, 1740, 146851.	1.1	13
149	Risk of burnout and stress in physicians working in a COVID team: A longitudinal survey. <i>International Journal of Clinical Practice</i> , 2021, 75, e14755.	0.8	13
150	Involvement of the ghrelin system in the maintenance and reinstatement of cocaine-motivated behaviors: a role of adrenergic action at peripheral β_1 receptors. <i>Neuropsychopharmacology</i> , 2022, 47, 1449-1460.	2.8	13
151	Pharmacological approaches to the management of alcohol addiction. <i>European Review for Medical and Pharmacological Sciences</i> , 2002, 6, 89-97.	0.5	13
152	Alcohol use disorder in community management of chronic liver diseases. <i>Hepatology</i> , 2023, 77, 1006-1021.	3.6	13
153	Baseline severity and the prediction of placebo response in clinical trials for alcohol dependence: A meta-regression analysis to develop an enrichment strategy. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 1722-1734.	1.4	12
154	Gut microbiome and metabolome in a non-human primate model of chronic excessive alcohol drinking. <i>Translational Psychiatry</i> , 2021, 11, 609.	2.4	12
155	Analysis of the T1288R Mutation of the Wilson Disease ATP7B Gene in Four Generations of a Family: Possible Genotype-Phenotype Correlation with Hepatic Onset. <i>Digestive Diseases and Sciences</i> , 2007, 52, 2570-2575.	1.1	11
156	Serum Insulin Levels Are Reduced by Intravenous Ghrelin Administration but Do Not Correlate with Alcohol Craving in Alcohol-Dependent Individuals. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyw048.	1.0	11
157	Intravenous administration of ghrelin increases serum cortisol and aldosterone concentrations in heavy-drinking alcohol-dependent individuals: Results from a double-blind, placebo-controlled human laboratory study. <i>Neuropharmacology</i> , 2019, 158, 107711.	2.0	11
158	Role of Molybdenum-Containing Enzymes in the Biotransformation of the Novel Ghrelin Receptor Inverse Agonist PF-5190457: A Reverse Translational Bed-to-Bench Approach. <i>Drug Metabolism and Disposition</i> , 2019, 47, 874-882.	1.7	11
159	Differences in Sociodemographic and Alcohol-Related Clinical Characteristics Between Treatment Seekers and Nontreatment Seekers and Their Role in Predicting Outcomes in the COMBINE Study for Alcohol Use Disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 2097-2108.	1.4	11
160	Neuroendocrine Response to Exogenous Ghrelin Administration, Combined With Alcohol, in Heavy-Drinking Individuals: Findings From a Randomized, Double-Blind, Placebo-Controlled Human Laboratory Study. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 464-476.	1.0	11
161	Anabolic androgenic steroids used as performance and image enhancing drugs in professional and amateur athletes: Toxicological and psychopathological findings. <i>Human Psychopharmacology</i> , 2022, 37, e2815.	0.7	11
162	Altering ethanol pharmacokinetics to treat alcohol use disorder: Can you teach an old dog new tricks?. <i>Journal of Psychopharmacology</i> , 2017, 31, 812-818.	2.0	10

#	ARTICLE	IF	CITATIONS
163	The Validity of the Montgomery-Asberg Depression Rating Scale in an Inpatient Sample with Alcohol Dependence. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 1220-1227.	1.4	10
164	Administration of the metabotropic glutamate receptor subtype 5 allosteric modulator GET 73 with alcohol: A translational study in rats and humans. <i>Journal of Psychopharmacology</i> , 2018, 32, 163-173.	2.0	10
165	Identifying and Characterizing Subpopulations of Heavy Alcohol Drinkers Via a Sucrose Preference Test: A Sweet Road to a Better Phenotypic Characterization?. <i>Alcohol and Alcoholism</i> , 2018, 53, 560-569.	0.9	10
166	Sensory cue reactivity: Sensitization in alcohol use disorder and obesity. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 124, 326-357.	2.9	10
167	Complexes of Ghrelin GHS-R1a, GHS-R1b, and Dopamine D ₁ Receptors Localized in the Ventral Tegmental Area as Main Mediators of the Dopaminergic Effects of Ghrelin. <i>Journal of Neuroscience</i> , 2022, 42, 940-953.	1.7	10
168	Effectiveness of spironolactone dispensation in reducing weekly alcohol use: a retrospective high-dimensional propensity score-matched cohort study. <i>Neuropsychopharmacology</i> , 2021, 46, 2140-2147.	2.8	9
169	Blood Biomarkers of Alcohol Use: A Scoping Review. <i>Current Addiction Reports</i> , 2021, 8, 500-508.	1.6	9
170	Involvement of the ghrelin system in the maintenance of oxycodone self-administration: converging evidence from endocrine, pharmacologic and transgenic approaches. <i>Molecular Psychiatry</i> , 2022, 27, 2171-2181.	4.1	9
171	A New Mutation of Wilson's Disease P-Type ATPase Gene in a Patient with Cirrhosis and Coombs-Positive Hemolytic Anemia. <i>Digestive Diseases and Sciences</i> , 2006, 51, 34-38.	1.1	8
172	Investigational therapies for the pharmacological treatment of alcoholism. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 17-30.	1.9	8
173	Hepatic, lipid and genetic factors associated with obesity: crosstalk with alcohol dependence?. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 120-128.	1.3	8
174	Neuroendocrine response to GABA-B receptor agonism in alcohol-dependent individuals: Results from a combined outpatient and human laboratory experiment. <i>Neuropharmacology</i> , 2018, 137, 230-239.	2.0	8
175	Effect of oral alcohol administration on plasma cytokine concentrations in heavy drinking individuals. <i>Drug and Alcohol Dependence</i> , 2021, 225, 108771.	1.6	8
176	OUP accepted manuscript. <i>Alcohol and Alcoholism</i> , 2021, , .	0.9	8
177	Tolerance to baclofen's sedative effect in alcohol-addicted patients: no dissipation after a period of abstinence. <i>Psychopharmacology</i> , 2005, 178, 351-352.	1.5	7
178	Editorial: Pharmacotherapy of Alcohol Dependence: Past, Present and Future Research. <i>Current Pharmaceutical Design</i> , 2010, 16, 2074-2075.	0.9	7
179	Alcohol addiction: toward a patient-oriented pharmacological treatment. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2157-2160.	0.9	7
180	Commentary: Doxazosin for Alcoholism. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, 191-193.	1.4	7

#	ARTICLE	IF	CITATIONS
181	A Population Pharmacokinetic Analysis of PF-5190457, a Novel Ghrelin Receptor Inverse Agonist in Healthy Volunteers and in Heavy Alcohol Drinkers. <i>Clinical Pharmacokinetics</i> , 2021, 60, 471-484.	1.6	7
182	The GABA-B receptor agonist baclofen helps patients with alcohol use disorder: why these findings matter. <i>Neuropsychopharmacology</i> , 2021, 46, 2228-2229.	2.8	7
183	Brain metabolite alterations related to alcohol use: a meta-analysis of proton magnetic resonance spectroscopy studies. <i>Molecular Psychiatry</i> , 2022, 27, 3223-3236.	4.1	7
184	Investigating the link between serum concentrations of brain-derived neurotrophic factor and behavioral measures in anxious alcohol-dependent individuals. <i>Alcohol</i> , 2020, 89, 75-83.	0.8	6
185	Echocardiographic markers of early alcoholic cardiomyopathy: Six-month longitudinal study in heavy drinking patients. <i>European Journal of Internal Medicine</i> , 2022, 101, 76-85.	1.0	6
186	Adjunctive Pharmacotherapy in the Treatment of Alcohol and Drug Dependence. , 2009, , 287-310.		5
187	Effect of Functionally Significant Deiodinase Single Nucleotide Polymorphisms on Drinking Behavior in Alcohol Dependence: An Exploratory Investigation. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 1665-1670.	1.4	5
188	Peripheral proinflammatory markers are upregulated in abstinent alcohol-dependent patients but are not affected by cognitive bias modification: Preliminary findings. <i>Drug and Alcohol Dependence</i> , 2019, 204, 107553.	1.6	5
189	Peptide-Liganded G Protein-Coupled Receptors as Neurotherapeutics. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 190-202.	2.5	5
190	Brief Report: Relationship Between Cotinine Levels and Peripheral Endogenous Concentrations of Oxytocin, Î²â€œEndorphin, and Orexin in Individuals With Both Alcohol and Nicotine Use Disorders. <i>American Journal on Addictions</i> , 2021, 30, 88-91.	1.3	5
191	Cardiovascular Consequences of Excessive Alcohol Drinking via Electrocardiogram. <i>Journal of Addictions Nursing</i> , 2021, 32, 39-45.	0.2	5
192	Thiamine administration to<i>all</i>patients with alcohol use disorder: why not?. <i>American Journal of Drug and Alcohol Abuse</i> , 2021, 47, 651-654.	1.1	5
193	Identifying Alcohol Use Disorder in Patients With Cirrhosis Reduces 30-Days Readmission Rate. <i>Alcohol and Alcoholism</i> , 2022, 57, 576-580.	0.9	5
194	High Ghrelin Levels in Post-treatment Euthyroid Patients with Hashimotoâ€™s Thyroiditis: a Case-control Preliminary Study. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2014, 122, 540-543.	0.6	4
195	Development and validation of an UPLC-MS/MS assay for quantitative analysis of the ghrelin receptor inverse agonist PF-5190457 in human or rat plasma and rat brain. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 5603-5613.	1.9	4
196	Development and validation of an assay for a novel ghrelin receptor inverse agonist PF-5190457 and its major hydroxy metabolite (PF-6870961) by LC-MS/MS in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1130-1131, 121820.	1.2	4
197	A neuroimaging investigation into the role of peripheral metabolic biomarkers in the anticipation of reward in alcohol use. <i>Drug and Alcohol Dependence</i> , 2021, 221, 108638.	1.6	4
198	A population-based investigation of the association between alcohol intake and serum total ghrelin concentrations among cigarette-smoking, non-alcohol-dependent male individuals. <i>Drug and Alcohol Dependence</i> , 2021, 226, 108835.	1.6	4

#	ARTICLE	IF	CITATIONS
199	An inpatient human laboratory study assessing the safety and tolerability, pharmacokinetics, and biobehavioral effect of GET 73 when co-administered with alcohol in individuals with alcohol use disorder. <i>Psychopharmacology</i> , 2021, , 1.	1.5	4
200	Superior vena cava thrombosis treated by angioplasty and stenting in a cirrhotic patient with peritoneovenous shunt. <i>Annals of Thoracic and Cardiovascular Surgery</i> , 2008, 14, 60-2.	0.3	4
201	Understanding plasma treatment effect on human acyl-ghrelin concentrations. <i>European Review for Medical and Pharmacological Sciences</i> , 2020, 24, 1585-1589.	0.5	4
202	Topiramate for alcoholism treatment: novel pharmacogenetic evidence for the journey to personalized medicine?. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 1541-1544.	1.0	3
203	Alcohol and Alcoholism: Then, Now and The Future of "The Red Journal". <i>Alcohol and Alcoholism</i> , 2018, 53, 637-638.	0.9	3
204	A role for the CD38rs3796863 polymorphism in alcohol and monetary reward: evidence from CD38 knockout mice and alcohol self-administration, [¹¹ C]-raclopride binding, and functional MRI in humans. <i>American Journal of Drug and Alcohol Abuse</i> , 2020, 46, 167-179.	1.1	3
205	From "The Red Journal", for the Retirement of Editor-in-Chief Philippe De Witte: A Fond and Grateful Farewell. <i>Alcohol and Alcoholism</i> , 2020, 55, 1-2.	0.9	3
206	Response to "Addiction is a social disease: just as tenable as calling it a brain disease". <i>Neuropsychopharmacology</i> , 2021, 46, 1713-1714.	2.8	3
207	Leptin Gene and Leptin Receptor Gene Polymorphisms in Alcohol Use Disorder: Findings Related to Psychopathology. <i>Frontiers in Psychiatry</i> , 2021, 12, 723059.	1.3	3
208	Effect of intravenous ghrelin administration, combined with alcohol, on circulating metabolome in heavy drinking individuals with alcohol use disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 2207-2216.	1.4	3
209	Marked Decrease of Serum Ca 125 Levels After Denver Shunt Placement in a Patient With Cirrhosis and Refractory Ascites. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1644-1646.	1.1	2
210	Modulating Morphine Context-Induced Drug Memory With Deep Brain Stimulation: More Research Questions by Lowering Stimulation Frequencies?. <i>Biological Psychiatry</i> , 2016, 80, 647-649.	0.7	2
211	The validity of the state-trait anxiety inventory and the brief scale for anxiety in an inpatient sample with alcohol use disorder. <i>Addiction</i> , 2021, 116, 3055-3068.	1.7	2
212	Synthesis of PF-6870961, a major hydroxy metabolite of the novel ghrelin receptor inverse agonist PF-5190457. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 50, 116465.	1.4	2
213	Commentary on Schmitz <i>et al</i> . (2017): Advancing medication development for addiction—behavioral and neuroimaging outcomes as indirect biomarkers of target engagement. <i>Addiction</i> , 2017, 112, 1869-1870.	1.7	1
214	Leveraging genetic data to investigate molecular targets and drug repurposing candidates for treating alcohol use disorder and hepatotoxicity. <i>Drug and Alcohol Dependence</i> , 2020, 214, 108155.	1.6	1
215	Alcohol-related changes in behaviors and characteristics from the baseline to the randomization session for treatment and non-treatment seeking participants with alcohol use disorder. <i>American Journal of Drug and Alcohol Abuse</i> , 2021, , 1-9.	1.1	1
216	Alcohol-medication interactions: A systematic review and meta-analysis of placebo-controlled trials. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 132, 519-541.	2.9	1

#	ARTICLE	IF	CITATIONS
217	Ghrelin: From a Gut Hormone to a Potential Therapeutic Target for Alcohol Addiction. FASEB Journal, 2019, 33, 499.3.	0.2	0
218	The Glucagon-Like Peptide-1 (GLP-1) System is Modulated by Acute and Chronic Exposure to Alcohol: Findings from Human Laboratory and Brain Postmortem Studies. FASEB Journal, 2019, 33, .	0.2	0